LUXTURNA: payments to doctors
Payments that named LUXTURNA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $8.5M
- Providers
- 755
- Transactions
- 1,209
- Average per transaction
- $6,991
The per-transaction average — $6,991 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 755 providers the average total is $11,195, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Spark Therapeutics, Inc. | $8,364,032 | 99.0% |
| Novartis Pharma AG | $87,948 | 1.0% |